The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
TRK inhibitors in TRK fusion-positive cancers
Open accessAbstract
TRK fusions are oncogenic drivers of various adult and paediatric cancers. The first-generation TRK inhibitors, larotrectinib and entrectinib, were granted landmark, tumour-agnostic regulatory approvals for the treatment of these cancers in 2018 and 2019, respectively. Brisk and durable responses are achieved with these drugs in patients, including those with locally advanced or metastatic disease. In addition, intracranial activity has been observed with both agents in TRK fusion-positive solid tumours with brain metastases and primary brain tumours. While resistance to first-generation TRK inhibition can eventually occur, next-generation agents such as selitrectinib (BAY 2731954, LOXO-195) and repotrectinib were designed to address on-target resistance, which is mediated by emergent kinase domain mutations, such as those that result in substitutions at solvent front or gatekeeper residues. These next-generation drugs are currently available in the clinic and proof-of-concept responses have been reported. This underscores the utility of sequential TRK inhibitor use in select patients, a paradigm that parallels the use of targeted therapies in other oncogenic driver-positive cancers, such as ALK fusion-positive lung cancers. While TRK inhibitors have a favourable overall safety profile, select on-target adverse events, including weight gain, dizziness/ataxia and paraesthesias, are occasionally observed and should be monitored in the clinic. These side-effects are likely consequences of the inhibition of the TRK pathway that is involved in the development and maintenance of the nervous system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · cited 1×
“Elucidation of the activity of pembrolizumab in tumours of any type with high levels of microsatellite instability (MSI-high) marked the first major success in this area [4].”
BackgroundZehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · cited 1×
“An increase in the adoption of more comprehensive, clinicalgrade sequencing platforms later promoted a recognition of the presence of targetable genomic alterations across multiple tumour types [2].”
BackgroundEfficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Self-citationAlectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704795 · Cited by 2,527 · cited 1×
“For comparison, the frequency of dose reduction with entrectinib [17], larotrectinib [16] and crizotinib [32] was 27%, 9% and 21%, respectively.”
BackgroundCrizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964 · cited 1×
“By way of illustration, the frequencies of treatment-related nausea, diarrhoea and transaminitis were lower with entrectinib [17] or larotrectinib [16] than with crizotinib [31], a multikinase inhibitor with a well-characterised safety profile that incidentally has minimal activity against TRK (Figure 2).”
BackgroundNTRK fusion-positive cancers and TRK inhibitor therapy
Cocco, E., Scaltriti, M., & Drilon, A. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0113-0 · Cited by 1,485
Self-citationFunctions of the neurotrophins during nervous system development: What the knockouts are teaching us
Snider, W. D. (1994) · Cell · doi:10.1016/0092-8674(94)90048-5 · Cited by 1,428
Gainor, J. F., Dardaei, L., Yoda, S., Friboulet, L., Leshchiner, I., Katayama, R., Dagogo-Jack, I., Gadgeel, S., Schultz, K., Singh, M., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0596 · Cited by 1,148
Severe sensory and sympathetic neuropathies in mice carrying a disrupted Trk/NGF receptor gene
Smeyne, R. J., Klein, R., Schnapp, A., Long, L. K., Bryant, S., Lewin, A., Lira, S. A., & Barbacid, M. (1994) · Nature · doi:10.1038/368246a0 · Cited by 981
Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor
Xu, B., Goulding, E. H., Zang, K., Cepoi, D., Cone, R. D., Jones, K. R., Tecott, L. H., & Reichardt, L. F. (2003) · Nature Neuroscience · doi:10.1038/nn1073 · Cited by 896
Drilon, A., Siena, S., Ou, S.-H. I., Patel, M., Ahn, M. J., Lee, J., Bauer, T. M., Farago, A. F., Wheler, J. J., Liu, S. V., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1237 · Cited by 826
Self-citationKlein, R., Smeyne, R. J., Wurst, W., Long, L. K., Auerbach, B. A., Joyner, A. L., & Barbacid, M. (1993) · Cell · doi:10.1016/0092-8674(93)90683-h · Cited by 699
Indo, Y., Tsuruta, M., Hayashida, Y., Karim, M. A., Ohta, K., Kawano, T., Mitsubuchi, H., Tonoki, H., Awaya, Y., & Matsuda, I. (1996) · Nature Genetics · doi:10.1038/ng0896-485 · Cited by 646
Klein, R., Silos-Santiago, I., Smeyne, R. J., Lira, S. A., Brambilla, R., Bryant, S., Zhang, L., Snider, W. D., & Barbacid, M. (1994) · Nature · doi:10.1038/368249a0 · Cited by 624
Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer
Vaishnavi, A., Capelletti, M., Le, A. T., Kako, S., Butaney, M., Ercan, D., Mahale, S., Davies, K. D., Aisner, D. L., Pilling, A. B., et al. (2013) · Nature Medicine · doi:10.1038/nm.3352 · Cited by 607
A de novo mutation affecting human TrkB associated with severe obesity and developmental delay
Yeo, G. S. H., Connie Hung, C.-C., Rochford, J., Keogh, J., Gray, J., Sivaramakrishnan, S., O'Rahilly, S., & Farooqi, I. S. (2004) · Nature Neuroscience · doi:10.1038/nn1336 · Cited by 607
Brain-Derived Neurotrophic Factor/TrkB Signaling in Memory Processes
Yamada, K., & Nabeshima, T. (2003) · Journal of Pharmacological Sciences · doi:10.1254/jphs.91.267 · Cited by 585
Laetsch, T. W., DuBois, S. G., Mascarenhas, L., Turpin, B., Federman, N., Albert, C. M., Nagasubramanian, R., Davis, J. L., Rudzinski, E., Feraco, A. M., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30119-0 · Cited by 552
Drilon, A., Ou, S.-H. I., Cho, B. C., Kim, D.-W., Lee, J., Lin, J. J., Zhu, V. W., Ahn, M.-J., Camidge, D. R., Nguyen, J., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0484 · Cited by 504 · cited 4×
“Similarly, repotrectinib has been shown to re-establish disease control after the development of kinase domain-mediated acquired resistance to a first-generation TRK inhibitor [28].”
BackgroundInfluentialSelf-citationImplementing Genome-Driven Oncology
Hyman, D. M., Taylor, B. S., & Baselga, J. (2017) · Cell · doi:10.1016/j.cell.2016.12.015 · Cited by 503
Drilon, A., Nagasubramanian, R., Blake, J. F., Ku, N., Tuch, B. B., Ebata, K., Smith, S., Lauriault, V., Kolakowski, G. R., Brandhuber, B. J., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0507 · Cited by 439
Self-citationAcquired Resistance to Crizotinib from a Mutation in CD74–ROS1
Awad, M. M., Katayama, R., McTigue, M., Liu, W., Deng, Y.-L., Brooun, A., Friboulet, L., Huang, D., Falk, M. D., Timofeevski, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215530 · Cited by 416
Doebele, R. C., Davis, L. E., Vaishnavi, A., Le, A. T., Estrada-Bernal, A., Keysar, S., Jimeno, A., Varella-Garcia, M., Aisner, D. L., Li, Y., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0443 · Cited by 388
Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance
Schram, A. M., Chang, M. T., Jonsson, P., & Drilon, A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.127 · Cited by 323
Self-citationArdini, E., Menichincheri, M., Banfi, P., Bosotti, R., De Ponti, C., Pulci, R., Ballinari, D., Ciomei, M., Texido, G., Degrassi, A., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0758 · Cited by 321
Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer
Russo, M., Misale, S., Wei, G., Siravegna, G., Crisafulli, G., Lazzari, L., Corti, G., Rospo, G., Novara, L., Mussolin, B., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0940 · Cited by 308
Drilon, A., Li, G., Dogan, S., Gounder, M., Shen, R., Arcila, M., Wang, L., Hyman, D. M., Hechtman, J., Wei, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw042 · Cited by 306
Self-citationMenichincheri, M., Ardini, E., Magnaghi, P., Avanzi, N., Banfi, P., Bossi, R., Buffa, L., Canevari, G., Ceriani, L., Colombo, M., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00064 · Cited by 299
Basket Trials and the Evolution of Clinical Trial Design in an Era of Genomic Medicine
Redig, A. J., & Jänne, P. A. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.8433 · Cited by 278
Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer
Farago, A. F., Le, L. P., Zheng, Z., Muzikansky, A., Drilon, A., Patel, M., Bauer, T. M., Liu, S. V., Ou, S.-H. I., Jackman, D., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000473485.38553.f0 · Cited by 229
Self-citationResistance to TRK inhibition mediated by convergent MAPK pathway activation
Cocco, E., Schram, A. M., Kulick, A., Misale, S., Won, H. H., Yaeger, R., Razavi, P., Ptashkin, R., Hechtman, J. F., Toska, E., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0542-z · Cited by 217
Self-citationLiu, D., Offin, M. D., Harnicar, S. J., Li, B. T., & Drilon, A. E. D. C. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s147381 · Cited by 131
Self-citationMechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers
Fuse, M. J., Okada, K., Oh‐hara, T., Ogura, H., Fujita, N., & Katayama, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0909 · Cited by 122
Ziegler, D. S., Wong, M., Mayoh, C., Kumar, A., Tsoli, M., Mould, E. V. A., Tyrrell, V. J., Khuong-Quang, D.-A., Pinese, M., Gayevskiy, V., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0251-2 · Cited by 116
Drilon, A. E. D. C., DuBois, S. G., Farago, A. F., Geoerger, B., Grilley‐Olson, J. E., Hong, D. S., Sohal, D. P. S., van Tilburg, C. M., Ziegler, D. S., Ku, N. C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.2006 · Cited by 79
Self-citationAshraf, S., Bouhana, K., Pheneger, J., Andrews, S. W., & Walsh, D. A. (2016) · Arthritis Research & Therapy · doi:10.1186/s13075-016-0996-z · Cited by 63
Robinson, G. W., Gajjar, A. J., Gauvain, K., Basu, E. M., Macy, M. E., Maese, L. D., Sabnis, A. J., Foster, J. H., Shusterman, S., Yoon, J. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.10009 · Cited by 62
Lassen, U., Albert, C. M., Kummar, S., van Tilburg, C. M., Dubois, S. G., Geoerger, B., Mascarenhas, L., Federman, N. C., Schilder, R. J., Doz, F., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy279.397 · Cited by 46
Self-citationLarotrectinib Demonstrates CNS Efficacy in TRK Fusion-Positive Solid Tumors
Rosen, E. Y., Schram, A. M., Young, R. J., Schreyer, M., Hechtman, J. F., Shu, C. A., Ku, N. C., Hyman, D. M., & Drilon, A. E. D. C. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00009 · Cited by 32
Self-citationRichardson, C. A., & Leitch, B. (2004) · The Journal of Comparative Neurology · doi:10.1002/cne.20386 · Cited by 31
Larotrectinib efficacy and safety in pediatric TRK fusion cancer patients.
van Tilburg, C. M., DuBois, S. G., Albert, C. M., Federman, N. C., Nagasubramanian, R., Geoerger, B., Orbach, D. H., Bielack, S., Shukla, N. N., Turpin, B. K., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.10010 · Cited by 20
Cited by
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,584
Wen, P. Y., Weller, M., Lee, E. Q., Alexander, B. M., Barnholtz-Sloan, J. S., Barthel, F. P., Batchelor, T. T., Bindra, R. S., Chang, S. M., Chiocca, E. A., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa106 · Cited by 1,168
First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Bauer, T. M., de Marinis, F., Felip, E., Goto, Y., Liu, G., Mazieres, J., Kim, D.-W., Mok, T., Polli, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2027187 · Cited by 1,099
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
Huang, L., Jiang, S., & Shi, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00977-0 · Cited by 456
Metadata
- Authors
- Drilon, A.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2019-11
- Volume
- 30
- Issue
- Suppl_8
- Pages
- viii23-viii30
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2983799945
- Cited by
- 291
- References
- 41
- FWCI
- 26.52
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.